Kornimate/medical-research-clean huggingface dataset:
evaluation of root coverage by connective graft and different root conditioning methods

Conditions: Gingival Recession

Summary: the aim of this study was to evaluate the effect of two root-conditioning agents used in conjunction with subepithelial connective graft technique on root coverage outcomes. one is citric acid plus tetracycline and the other is antimicrobial photodynamic therapy.

citric acid plus tetracycline has properties of root surface decontamination, surface demineralization and exposure of collagen fibers. antimicrobial photodynamic therapy has been widely used in periodontics to obtain reduction of periodontopathogenic bacteria with absence of systemic side effects and minimal bacterial resistance. also, it has properties of root demineralization and exposure of collagen fibers. these properties may enhance root coverage in procedures of subepithelial connective graft.

Eligibility criteria:
inclusion criteria: * gingival recession - miller's class i or ii (2 to 5 mm of height) at least in one tooth * indication of root coverage by dentin hypersensitivity or esthetic exclusion criteria: * smokers * pregnancy * systemic medication use that could impair wound healing or surgery procedure * systemic diseases as diabetes, uncontrolled hypertension, coagulation diseases, kidney diseases.

Keywords: gingival recession
tiotropium and salmeterol pk study in copd patients

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: the primary objective of this study is to characterize the pharmacokinetics (i.e. systemic exposure to tiotropium and salmeterol) of tiotropium qd + salmeterol qd or bid versus tiotropium qd and salmeterol bid following 4-week treatment periods in patients with chronic obstructive pulmonary disease (copd).


Eligibility criteria:
inclusion criteria: copd patients of \>= 40 years old with moderate to severe copd who are current or ex-smokers with a smoking history of at least 10 pack-years exclusion criteria: 1. recent history of myocardial infarction, life-threatening cardiac arrhythmia or hospitalisation for cardiac failure 2. history of asthma 3. malignancy requiring treatment within past 5 years 4. life-threatening pulmonary obstruction, cystic fibrosis or clinically evident bronchiectasis 5. known active tuberculosis 6. pregnant or nusing women 7. known hypersensitivity to components of the study medication
evaluation of early mobilization protocol in patients undergoing gastrointestinal surgery

Conditions: Gastrointestinal Diseases

Summary: in this study, the investigators aimed to evaluate the early mobilization protocol created in accordance with the accelerated recovery guide after surgery in patients undergoing gastrointestinal surgery.

this study is an experimental study. the participants in the control group are applied to the mobilization applied in routine clinics. the participants in the intervention group are applied to the mobilization protocol created in accordance with the enhanced recovery after surgery (eras) guidelines. it is planned to evaluate the postoperative mobilization process of both groups. in this study, the researchers aimed to evaluate the early mobilization protocol created in accordance with the accelerated recovery guide after surgery in patients undergoing gastrointestinal surgery.

Eligibility criteria:
inclusion criteria: * being 18 years of age or older * agreeing to participate in the study * being able to understand, speak turkish or have no obstacle to communication * having undergone open gastrointestinal surgery * having an american society of anesthesiologists (asa) score \<iv * being fully independent according to the modified barthel index during the pre-operative period * staying in the hospital for at least 48 hours after the surgery * having a phone * agreeing to download the 'stepsapp pedometer' application to their phone * agreeing to carry the phone with them during the post-operative mobilization processes exclusion criteria: * being taken into emergency surgery * having had major gastrointestinal surgery before * having a diagnosis that may restrict mobilization (neurological, cardiovascular, respiratory and musculoskeletal comorbidities) * high risk of falling in the preoperative period * using medication that may affect mobilization * having a diagnosis of any psychiatric disease * having a nutritional risk score score of ≥3 * being in contact isolation * being morbidly obese * being in intensive care for more than 24 hours during the postoperative period * having an intubation period of more than 24 hours during the postoperative period * developing a complication that may prevent mobilization after surgery * withdrawing from participating in the study,

Keywords: gastrointestinal diseases enhanced recovery after surgery early ambulation
a study to evaluate physiologic dentin regeneration and safety of kh001 in the administration of erupted wisdom tooth with dentin caries

Conditions: Dentin Caries

Summary: the purpose of this study is to evaluate physiologic dentin regeneration and safety of kh001 in the administration of erupted wisdom tooth with dentin caries

the design is a single site, double-blind, randomized study. phase 2 study to evaluate physiologic dentin regeneration and safety of kh001. the total duration of the study will be approximately 5 to 9 weeks.

Eligibility criteria:
inclusion criteria: * is between 19 and 35 of age by the time of the screening * has signed written informed consent in the study * subject who either have no pain in the affected tooth, or can endure pain until the day of tooth extraction exclusion criteria: * is allergic to the active ingredient or other ingredients used in the investigational product * have participated in another clinical study within 30 days from screening visit and have a history of administration/application of investigational product/device * is judged by the investigator as ineligible for participation for other reasens

Keywords: wisdom tooth dentin caries
a phase ii study of irinotecan in 3 line or more therapy in local recurrence or metastatic breast cancer

Conditions: Stage IIIB, IV, Recurrent, and Metastatic Breast Cancer

Summary: a phase ii study of irinotecan in 3 line or more therapy in local recurrence or metastatic breast cancer. evaluate the effect and safety of irinotecan in local recurrence or metastatic breast cancer patients who recieved anthracycline or taxane drugs. the primary endpoint is disease control rate and progression free survival. the second endpoint is 3 or 4 grade adverse events 、overall survival.all the patients will recieve this therapy till disease progress or other occurrence of withdrawal standards.

a phase ii study of irinotecan in 3 line or more therapy in local recurrence or metastatic breast cancer. evaluate the effect and safety of irinotecan in local recurrence or metastatic breast cancer patients who recieved anthracycline or taxane drugs. the primary endpoint is disease control rate and progression free survival. the second endpoint is 3 or 4 grade adverse events 、overall survival. irinotecan 100mg/m2,iv,day1,day8,every 3cycles.if no ae happens, increase irinotecan dose to125mg/m2 at the second cycle.all the patients will recieve this therapy till disease progress or other occurrence of withdrawal standards.

Eligibility criteria:
inclusion criteria: * mestatic breast cancer patients whose disease recurrent after using anthracycline or taxane drugs exclusion criteria: * heart disease.etc
impact of covid-19 pandemic on perceived exercise benefits and barriers

Conditions: COVID; Isolation, Social

Summary: it is aimed to determine the physical activity level and exercise benefits and barriers caused by covid-19 pandemic and reveal the relationship between them.

study hypothesis that people are tend to be physically inactive while covid-19 pandemic. it is aimed to determine the exercise benefits and barriers caused by covid-19 pandemic and reveal the relationship among gender, age, marial status and physical activity level.

Eligibility criteria:
inclusion criteria: * being turkish * understanding turkish * being between the age of 15 - 65 * being literate * have internet access exclusion criteria: * having a disable condition to exercise * having missing value on outcome measures * giving incomprehensible answering

Keywords: covid 19 physical activity level exercise benefits and barriers turkish society social isolation
intrathecal chemotherapy for central nervous system metastasis in retinoblastoma

Conditions: Retinoblastoma, Extraocular

Summary: retinoblastoma is the most common intraocular malignancy in infancy and childhood. the overall survival rate of retinoblastoma was reported to exceed 95% when children were early diagnosed with localized intraocular phase. the advanced retinoblastoma cases with central nervous system metastasis (cns)is associated with exceedingly poor prognosis. cns metastasis is the main cause of death in retinoblastoma. meningeal involvement combined with spinal cord membrane involvement might be due to the meninges invasion and/or the spreading of csf. as the most sensitive drug to retinoblastoma tumor cells in vitro, melphalan is the most important drug in the local treatment of retinoblastoma, and it is also an irreplaceable drug in the current eye preservation treatment, which greatly improves the success rate of eye preservation for advanced retinoblastoma. according to the research and the practice of vitreous injection (melphalan), the drug concentration in vitreous can effectively kill retinoblastoma tumor cells. it is reasonable to speculate that the tumor cells in csf can be effectively killed by melphalan. therefore, based on the above background, this study will explore the effectiveness and feasibility of intrathecal injection of melphalan in patients with cns metastasis of retinoblastoma through a multicenter prospective study.


Eligibility criteria:
inclusion criteria: * the pathological diagnosis was retinoblastoma. according to the irss (international retinoblastoma staging system) staging system, the stage was ivb * csf tumor cells on cytology, or radiographic evidence of nm on mri scans and histologic diagnosis of systemic malignancy needed * kps≥60% * adequate bone marrow and organ function * the parents signed the informed consent and were willing to accept the treatment and follow-up. exclusion criteria: * 1.eye diseases other than retinoblastoma * the eyes were infected within 30 days before screening * there was a history of surgery and / or unhealed wound within 1 month before enrollment . * those who have allergic reaction or allergic history to chemotherapeutic drugs. * infectious diseases requiring oral, intramuscular or intravenous administration. * patients with systemic immune diseases. * active disseminated intravascular coagulation. * abnormal coagulation function. * abnormal bone marrow and organ function. * uncontrollable clinical problems. * the researchers believe that those who need to be excluded.

Keywords: retinoblastoma central metastases intrathecal chemotherapy
minimally invasive surgery (mis) for spine metastases

Conditions: Spine Metastases

Summary: the purpose of this study is to collect information on the effect of minimally invasive spine tumor decompression on treated patients. this treatment option is less invasive that the standard surgical decompression and is expected to result in better wound healing, decreased tissue trauma, and decreased pain after surgery.

this is a prospective study designed to analyze the impact that minimally invasive spine tumor decompression has upon quality of life, neurological morbidity, pain, and mortality. prospective findings will be compared with historical controls to determine whether the minimally invasive approach offers better outcomes than traditional treatment methods.

Eligibility criteria:
inclusion criteria: * undergone minimally invasive surgery * over 18 years of age exclusion criteria: * unable to give consent

Keywords: minimally invasive surgery
observational program of zemplar in patients with end stage chronic kidney disease and parathyroid disorder on hemodialysis in the russian federation

Conditions: Secondary Hyperparathyroidism

Summary: eighty-six eligible participants with secondary hyperparathyroidism will be enrolled at thirteen sites in russia. planned therapy will be six months. participants with stage 5 chronic kidney disease and with hyperparathyroidism on hemodialysis will be included into the study. ability of zemplar, (paricalcitol) to lower intact parathyroid hormone level will be assessed during the study.

eighty-six eligible participants with secondary hyperparathyroidism will be enrolled at thirteen sites in russia. study drug will be administered per local prescribing guidelines. planned therapy is six months. intact parathyroid hormone will be measured at the screening visit. all participants who meet the inclusion criteria and fail to meet the exclusion criteria will be included in the study. adverse events will be monitored throughout the observation period (and up to 30 days after the last dose of zemplar). ability of zemplar to lower intact parathyroid hormone level will be assessed throughout the study. proportion of participants with the level of intact parathyroid hormone 150 - 300 pg/ml was stated as primary endpoint. calcium and phosphorus elevation will be also measured throughout the study. the selected population is representative in relation to those who will take zemplar in routine practice. participants with contraindications to zemplar therapy (as per the local label) will not be included in the study.

Eligibility criteria:
inclusion criteria: 1. age 18-65 years 2. chronic kidney disease stage 5 receiving hemodialysis 3. authorization (consent) for use/disclosure of data signed by the patient 4. planned prescription of zemplar treatment due to fair clinical need and irrespectively of the participation in the current program according to the local label within 2 weeks after screening into the program 5. screening intact parathyroid hormone level (measured not earlier than 1 month before first dose of zemplar) between 300 and 900 pg/ml exclusion criteria: 1. contraindications to zemplar as indicated in approved label, including but not limited to hypersensitivity, hypervitaminosis d (serum d3 level above 32 ng/ml), concomitant use of vitamin d or phosphates, lactation period, pregnancy 2. any experimental drug within the period of 30 days before the inclusion into the program 3. screening ca x p \> 65 mg˄2/dl˄2 4. screening normalized serum total calcium \> 10.2 mg/dl 5. necessity for calcitonin maintenance oral or intravenous glucocorticoids, or other drugs that could have affected calcium or bone metabolism, other than females on stable estrogen and/or progestin therapy

Keywords: secondary hyperparathyroidism chronic renal insufficiency
from fetal-maternal interface immune tolerance to endometrial cancer immune escape: potential targets for immunotherapy

Conditions: Endometrial Cancer

Summary: non-interventional retro-prospective study on endometrial tissue samples taken from surgically treated patients.

the picture of precisely coordinated immune adaptations over time at the maternal-fetal interface level and altered in pregnancy complications, could reveal a specific "immune clock" in tumors. the study aims to decipher mechanisms of immunodeficiency by helping to predict recurrence in patients with endometrial cancer and identify molecular pathways that are turned on or off in progression from lesions early to advanced neoplasia. this will allow the discovery of potential immunotherapy targets to interfere with the immune escape activation process or to reactivate/re-educate the immune response.

Eligibility criteria:
inclusion criteria: * age \>18 years; * histological diagnosis of endometrial hyperplasia with and without atypia, carcinoma of the endometrium histotype endometrioid at any stage of the disease (figo i-iv), patients subjected to hysterectomy for benign extra-endometrial pathology, patients with recurrence/metastasis from endometrioid endometrial carcinoma that are subjected to surgery; * adequate biological material to be able to carry out the analyzes previously described; * written informed consent (only for patients in the prospective part and/or in follow-up); * for the retrospective part: availability of samples adequately stored at the institute biobank and availability of follow-up data. exclusion criteria: * comorbidities not controlled with adequate medical therapy; * infections of the endometrial cavity (pyometra); * synchronous tumors; * neoadjuvant treatments; * previous radiation treatments on the pelvic region.
the minimum effective concentration of lidocaine for ultrasound-guided axillary block for arterio-venous fistula creation surgery

Conditions: Anesthesia

Summary: the arteriovenous fistula creation (avf creation) surgery is essential among patients with end stage renal disease who require hemodialysis. the fistula usually locates at forearm, and is created by connecting artery and vein through surgery. patients undergone hemodialysis through the fistula six weeks later if fistula becoming mature, which means patent vessel diameter and enough flow for hemodialysis. the primary failure rate of arteriovenous fistula creation is about 20% to 40% according to previous research data. thrombosis is the most common cause of fistula failure, which require surgical intervention after arteriovenous fistula surgery. anesthetic technique influences surgical outcome of arteriovenous fistula. general anesthesia, regional anesthesia, and local anesthesia are both wide-used methods. regional anesthesia with nerve block remains the most popular method for arteriovenous fistula creation. the vessel dilation effect of regional anesthesia helps not only dilatation of artery and vein, but also the fistula itself, and promotes the successful functional dialysis. various type of nerve block are used as anesthetic method for avf creation surgery. people requiring hemodialysis usually have multiple underlying disease involving other major organ such as heart, lung, liver, and the endocrine system. they are more vulnerable to systemic intravenous anesthetic medication. the metabolic rate and pharmacodynamics of local anesthetic may also alter due to multiple systemic disease when compared with healthy adults. the optimal concentration of lidocaine for avf creation when using axillary block has not yet been studied. this research is conducted for dosing response of different concentration of lidocaine when using axillary block for avf creation surgery. we aim to investigate the optimal low effective concentration, the mec90, which defined as 90% of patients can tolerate the operation at this concentration.


Eligibility criteria:
inclusion criteria: * asa classification i to iii * operation site : first time undergone surgery exclusion criteria: * asa classification iv to v * previous operation at surgical site before * allergy to local anesthetics * infectious state of injection point * neuromuscular disease causing preoperative numbness or weakness of extremities * history of vascular thromboembolism including stroke, pulmonary embolism * peripheral neuropathy * patient with psychiatric disease * coagulopathy, or patient taking anti-coagulant
mini-crush or controlled balloon-crush for true coronary bifurcation lesions

Conditions: Coronary Bifurcation Lesions; Death; Myocardial Infarction (MI); Stent Thrombosis; Stroke

Summary: the mini-crush technique is one of the leading 2-stent techniques frequently applied by interventional cardiologists to treat complex bifurcation lesions. in the last 20 years, many technical innovations and iterations of mini-crush technique have been developed, and it maintains its popularity among invasive cardiologists. moreover, mini-crush and double kissing-crush techniques have been compared in terms of clinical results in both left main and non-left main coronary bifurcation patient populations and no significant difference was found. however, the most important challenges of the mini-crush technique are the rewiring and advancement of a 1:1 non-compliant side-branch balloon after the main branch stent has been implanted. these challenges usually necessitate the use of a low profile balloon or additional support maneuvers (such as anchor balloon). recently, a novel modified mini-crush-crush technique (controlled balloon-crush) has been introduced to the literature and is one of the most up-to-date crush techniques. the main advantage of this technique over the contemporary mini-crush technique is that the side branch can be easily rewired and the 1:1 size non-compliant balloon can easily pass through the crushed stent structure in the ostial part of the side branch. the basic rationale of this is that the crushing of the side branch stent is done in a more controlled manner (by slowly deflation of the side branch stent balloon) and this causes less disruption of the stent cells. this prospective observational study aims to assess the procedural and 1-year clinical outcomes of the contemporary mini-crush and controlled balloon-crush (modified mini-crush) double stenting techniques in patients with true coronary bifurcation lesions.


Eligibility criteria:
inclusion criteria: * aged \>18 * pci with mini-crush or controlled balloon-crush * complex coronary bifurcation lesion (medina 0.1.1 and medina 1.1.1) exclusion criteria: * non-complex bifurcation anatomy * bail-out 2-stent (reverse mini-crush or reverse controlled balloon-crush) * st-elevation myocardial infarction * cardiogenic shock status * in-stent restenosis * a history of coronary artery bypass grafting * implantation of bare-metal stent * end-stage hepatic or renal disease * \<1-year life expectancy

Keywords: coronary bifurcation death revascularization stenting
role and outcome of endovascular revascularization of chronic limb ischaemia

Conditions: Limb Ischemia, Critical

Summary: identify the safety and efficacy of percutaneous transluminal angioplasty in critical limb ischaemia patients with chronic kidney dieases

patients with chronic kidney diseases are at higher risk of developing peripheral artery diseases needing revascularization of diseased arteries via endovascular transluminal angioplasty

Eligibility criteria:
inclusion criteria: * all patients with chronic kidney diseases on medical treatment or on dialysis and have critical limb ischaemia exclusion criteria: * patients with acute renal failure and lower limb ischaemia. * chronic kidney diseased patients underwent previous intervention or surgery for lower limb ischaemia. * patients presented with acute limb ischaemia